Kazia's Losses Mount to A$134.8M Amidst Plummeting Licensing Revenue

Ticker: KZIA · Form: 20-F · Filed: Nov 7, 2025 · CIK: 1075880

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, Net Losses, Dilution Risk, Early-Stage Pharma, SEC Filing, NASDAQ

TL;DR

**Kazia's A$134.8 million in accumulated losses and near-zero revenue mean this biotech is a high-risk bet on unproven clinical trials, requiring more dilutive funding to survive.**

AI Summary

KAZIA THERAPEUTICS LTD reported significant net losses for the fiscal year ended June 30, 2025, totaling A$20.7 million, following losses of A$26.8 million in 2024 and A$20.5 million in 2023. The company's accumulated losses reached A$134.8 million as of June 30, 2025. Revenue for 2025 was a mere A$42 thousand, derived from licensing development-stage drug candidates, a sharp decline from A$2.3 million in 2024. KAZIA has not generated revenue from product sales in prior financial years. The company raised A$16 million from the sale of American Depositary Shares (ADSs) during the year ended June 30, 2025, but explicitly states a need for additional funding to advance its research and development programs and pursue regulatory clearances. Two ADS ratio changes were effected: one on October 28, 2024, from 1 ADS to 10 ordinary shares to 1 ADS to 100 ordinary shares, and another on April 17, 2025, from 1 ADS to 100 ordinary shares to 1 ADS to 500 ordinary shares, indicating potential efforts to manage share price or investor perception. The company's future profitability hinges on the successful development and regulatory approval of its product candidates, which are currently in clinical trials.

Why It Matters

Kazia's continued significant net losses and minimal revenue from licensing, dropping from A$2.3 million in 2024 to A$42 thousand in 2025, signal a precarious financial position for investors. The company's reliance on equity financing, including the A$16 million raised in 2025, and the explicit need for further funding, suggest potential for substantial shareholder dilution. For employees and customers, the success of their two lead product candidates in clinical trials is paramount, as failure could jeopardize the company's continuity. In the competitive biotech landscape, Kazia's struggle to generate consistent revenue from its development-stage assets highlights the high-risk nature of drug development and the intense capital requirements.

Risk Assessment

Risk Level: high — KAZIA THERAPEUTICS LTD has incurred accumulated losses of A$134.8 million as of June 30, 2025, and reported a net loss of A$20.7 million for the fiscal year 2025. Revenue plummeted from A$2.3 million in 2024 to A$42 thousand in 2025, indicating a severe lack of sustainable income. The company explicitly states it will need additional funding, which is likely to substantially dilute existing shareholders, as evidenced by the A$16 million raised from ADS sales in 2025.

Analyst Insight

Investors should exercise extreme caution and consider KAZIA a highly speculative investment. Given the significant accumulated losses, minimal revenue, and explicit need for further funding, potential for substantial dilution is high. Only investors with a high-risk tolerance and a long-term horizon, who are comfortable betting on the success of early-stage clinical trials, should consider a position.

Financial Highlights

debt To Equity
N/A
revenue
A$42,000
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
A$-20,700,000
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
-98.2%

Revenue Breakdown

SegmentRevenueGrowth
Licensing Development-Stage Drug CandidatesA$42,000-98.2%

Key Numbers

Key Players & Entities

FAQ

What were Kazia Therapeutics' net losses for the fiscal year ended June 30, 2025?

Kazia Therapeutics reported a net loss of A$20.7 million for the fiscal year ended June 30, 2025. This follows net losses of A$26.8 million in 2024 and A$20.5 million in 2023.

How much revenue did Kazia Therapeutics generate in fiscal year 2025?

Kazia Therapeutics generated A$42 thousand in revenue during fiscal year 2025, primarily from the licensing of development-stage drug candidates. This is a significant decrease from A$2.3 million in revenue generated in 2024.

What were Kazia Therapeutics' accumulated losses as of June 30, 2025?

As of June 30, 2025, Kazia Therapeutics had accumulated losses totaling A$134.8 million, reflecting its history of significant research and development expenditures without corresponding product sales.

How did Kazia Therapeutics fund its operations in the past year?

During the year ended June 30, 2025, Kazia Therapeutics raised A$16 million from the sale of American Depositary Shares (ADSs). Historically, operations have been financed through equity issuances, Australian government grants, and collaboration partner payments.

What is the current ADS ratio for Kazia Therapeutics?

As of April 17, 2025, Kazia Therapeutics effected an ADS ratio change to one ADS representing five hundred (500) ordinary shares. This followed an earlier change on October 28, 2024, to one ADS representing one hundred (100) ordinary shares.

What are the primary risks to investors in Kazia Therapeutics?

Key risks include significant net losses and accumulated losses (A$134.8 million), the need for additional funding which will likely dilute existing shareholders, and the inherent unpredictability and high costs associated with clinical trials and regulatory approvals for its two lead product candidates.

Does Kazia Therapeutics expect to achieve profitability soon?

No, Kazia Therapeutics anticipates that it will continue to incur significant net losses for the foreseeable future and explicitly states it may never achieve or maintain profitability, as it does not expect to generate revenue from commercializing product candidates for the foreseeable future.

What are Kazia Therapeutics' main business objectives that require additional funding?

Kazia Therapeutics needs additional funding to advance its research and development programs, pursue regulatory clearances, defend intellectual property rights, establish commercial scale manufacturing facilities, develop marketing and sales capabilities, and fund operating expenses.

What impact could the failure of Kazia Therapeutics' product candidates have on the company?

The failure of one or both of Kazia Therapeutics' two product candidates currently in clinical trials to show benefit to patients could materially and adversely affect the continuity of its business and its financial condition, potentially leading to a cessation or scaling back of operations.

Where are Kazia Therapeutics' principal executive offices located?

Kazia Therapeutics' principal executive offices are located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney, New South Wales 2000, Australia.

Risk Factors

Industry Context

The biotechnology sector, particularly companies focused on oncology therapeutics like Kazia, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Success is often binary, depending on clinical trial outcomes and market adoption. The competitive landscape is intense, with numerous companies vying for breakthroughs in treating complex diseases.

Regulatory Implications

Kazia operates within a highly regulated pharmaceutical industry. The company must navigate stringent FDA and other global regulatory body requirements for drug development, clinical trials, and marketing approval. Failure to meet these standards or unexpected regulatory feedback can lead to significant delays or outright rejection of product candidates.

What Investors Should Do

  1. Monitor cash runway and future financing needs.
  2. Closely follow clinical trial progress and results.
  3. Evaluate the impact of ADS ratio changes.

Key Dates

Glossary

American Depositary Shares (ADSs)
Securities traded in the U.S. that represent shares of a foreign company's stock. (Kazia Therapeutics raises capital through the sale of ADSs, and changes in its ADS ratio directly impact the number of ordinary shares represented by each ADS.)
Development-stage drug candidates
Potential new drugs that are undergoing research and clinical testing but have not yet received regulatory approval for sale. (Kazia's revenue is derived from licensing these early-stage assets, and its future success hinges on their progression through clinical trials and regulatory approval.)
Clinical trials
A research study conducted with people to answer a question about a new treatment, diagnostic test, or other health-related issue. (Kazia's product candidates are in clinical trials, and their outcomes are critical determinants of the company's future viability and potential for revenue generation.)

Year-Over-Year Comparison

Kazia Therapeutics has seen a dramatic decrease in revenue for the fiscal year ended June 30, 2025, falling to A$42,000 from A$2.3 million in the prior year, a decline of 98.2%. This revenue drop, coupled with continued net losses (A$20.7 million in 2025 vs. A$26.8 million in 2024), highlights ongoing financial challenges. The company has raised A$16 million through ADS sales, indicating a reliance on equity financing to cover its operational deficits. No new significant risks appear to have emerged, but existing risks related to clinical development and funding remain highly relevant.

Filing Stats: 4,486 words · 18 min read · ~15 pages · Grade level 16.1 · Accepted 2025-11-07 16:01:45

Key Financial Figures

Filing Documents

tem 18

Item 17Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Table of Contents TABLE OF CONTENTS

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 1 PART I 2 Item 1. Identity of Directors, Senior Management and Advisors 2 Item 2. Offer Statistics and Expected Timetable 2 Item 3. Key Information 2 Item 4. Information on the Company 32 Item 4A. Unresolved Staff Comments 47 Item 5. Operating and Financial Review and Prospects 47 Item 6. Directors, Senior Management and Employees 55 Item 7. Major Shareholders and Related Party Transactions 65 Item 8. Financial Information 67 Item 9. The Offer and Listing 68 Item 10. Additional Information 69 Item 11.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 81 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 81 PART II 83 Item 13. Defaults, Dividend Arrearages and Delinquencies 83 Item 14. Material Modifications to the Rights of Security Holders and the Use of Proceeds 83 Item 15.

Controls and Procedures

Controls and Procedures 83 Item 16. [Reserved] 84 Item 16A. Audit Committee Financial Expert 84 Item 16B. Code of Ethics 84 Item 16C. Principal Accounting Fees and Services 84 Item 16D. Exemptions from the Listing Standards for Audit Committees 85 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 85 Item 16F. Changes in Registrant's Certifying Accountant 85 Item 16G. Corporate Governance 85 Item 16H. Mine Safety Disclosure 86 Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 86 Item 16J. Insider trading policies 86 Item 16K. Cybersecurity 87 PART III 87 Item 17.

Financial Statements

Financial Statements 87 Item 18.

Financial Statements

Financial Statements 87 Item 19. Exhibits 88 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 20-F includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "may," "will," "intend," "plan," "believe," "anticipate," "expect," "estimate," "predict," "potential," "continue," "likely," or "opportunity," the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, in "Business Overview" and "Operating and Financial Review and Prospects" in this Annual Report on Form 20-F. These forward-looking statements include, without limitation, statements about the following: the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our clinical programs being executed on timelines provided and reliance on our contract research organizations (CROs) and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs, and the ability to successfully submit the necessary applications or to obtain the necessary clearances; the ability to secure, maintain and

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing